Stryker (NYSE:SYK) Announces Earnings Results, Beats Estimates By $0.20 EPS

Stryker (NYSE:SYK) posted its quarterly earnings data on Thursday. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20, Zacks reports. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker updated its FY 2026 guidance to 14.950-15.100 EPS.

Stryker Trading Down 1.1%

Shares of SYK traded down $3.88 during mid-day trading on Thursday, reaching $348.37. The stock had a trading volume of 2,736,518 shares, compared to its average volume of 2,362,387. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker has a 52-week low of $281.00 and a 52-week high of $401.99. The business’s fifty day moving average is $316.38 and its 200 day moving average is $335.11. The firm has a market cap of $133.55 billion, a price-to-earnings ratio of 40.32, a P/E/G ratio of 2.22 and a beta of 0.77.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s payout ratio is presently 40.74%.

Insider Buying and Selling

In other news, VP M Kathryn Fink sold 3,500 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. This represents a 95.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 323,264 shares of company stock worth $100,659,489. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Atlas Capital Advisors Inc. acquired a new stake in Stryker during the fourth quarter worth $27,000. United Financial Planning Group LLC acquired a new position in shares of Stryker in the 3rd quarter valued at $27,000. Strive Asset Management LLC purchased a new position in shares of Stryker during the 3rd quarter worth $30,000. Birchwood Financial Partners Inc. purchased a new position in shares of Stryker during the 4th quarter worth $35,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Stryker during the 4th quarter worth about $49,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported quarterly earnings per share of $3.69, exceeding the consensus estimate of $3.49 by $0.20. Revenue reached approximately $6.59 billion, broadly ahead of expectations, while net income totaled $1.28 billion. Stryker quarterly earnings press release
• Positive Sentiment: Management said it has made progress restoring operations following the March cyberattack, suggesting disruption-related risks are becoming more manageable. Stryker Logs Higher Profit and Revenue Amid Cyberattack Recovery
• Positive Sentiment: UBS initiated coverage with a Buy rating and a $400 price target, indicating analysts see further upside based on Stryker’s medical-device portfolio and growth prospects. UBS Stryker coverage
• Positive Sentiment: The launch of the Mako RPS platform expands access to Stryker’s robotic knee-surgery technology and could support longer-term procedure growth. Stryker Launches Mako RPS
• Neutral Sentiment: Stryker maintained fiscal 2026 EPS guidance of $14.95–$15.10, with the midpoint close to analyst expectations. The update therefore provides stability but limited incremental upside.
• Negative Sentiment: Investors remain focused on the financial and operational effects of the cyberattack, while tariffs and inflation may pressure margins across medical-product manufacturers despite resilient demand. Medical product industry earnings risks

Analysts Set New Price Targets

Several equities analysts have recently weighed in on SYK shares. The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 target price on shares of Stryker in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research note on Friday, May 1st. Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Leerink Partners dropped their target price on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Finally, BTIG Research set a $371.00 price target on shares of Stryker in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $393.39.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.